OncLive TV

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

Melvin J. Silverstein, MD, FACS, medical director, Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, Hoag Memorial Hospital Presbyterian, compares oncoplastic surgery with mastectomy for patients with breast cancer.

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.

Edith Mitchell, MD, Prof of Medicine and Medical Oncology at Thomas Jefferson University, Director of the Center to Eliminate Cancer Disparities at the Sidney Kimmel Cancer Center at Thomas Jefferson University, discusses racial disparities in breast and prostate cancer.

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the research that led to the FDA approval of neoadjuvant pertuzumab as part of a combination regimen for patients with HER2-positive breast cancer.

Joe O'Sullivan, MD, discusses the efficacy of radium-223 when combined with enzalutamide and/or abiraterone in an international early access program for the treatment of patients with metastatic castration-resistant prostate cancer.

Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

Nadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Aleksandar Sekulic, MD, PhD, chief resident associate, Dermatology, Clinician Investigator Training Program, Mayo Clinic, discusses the rationale for molecular testing in patients with advanced melanoma.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses idelalisib (Zydelig) combinations in CLL.

Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation of radiotherapy using induction chemotherapy in locally advanced head and neck squamous cell cancer.

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, gives advice for community-based oncologists regarding HER2 testing and interpretation of the results.

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California, Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.

Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses adding platinum-based therapy to the neoadjuvant setting for the treatment of patients with triple-negative breast cancer.

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the ongoing phase III ADAPT trial, which examines AGS-003 combined with sunitinib for the treatment of patients with mRCC.

Lawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.

Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Adam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).

Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

Vincent Vandecaveye, MD, PhD, University Hospitals Leuven, discusses developments of magnetic resonance imaging, specifically diffusion MRI, as a method to differentiate tumors and disease stages.

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the overall survival results of the COMBI-d study, which examined the combination of dabrafenib and trametinib for the treatment of patients with unresectable or metastatic BRAF V600-mutated melanoma.

Stephen Rosenberg, MD, University of Wisconsin School of Medicine and Public Health, discusses a study examining if online patient information provided by National Cancer Institute (NCI)-designated cancer center websites is too complex for general readership.